Key result
SGLT2 inhibitors reduced the incidence of statin-induced abnormal blood glucose compared to conventional treatment in non-diabetic patients with HFrEF after PCI.
Why the study?
Long-term statin therapy is associated with increased risk of new-onset diabetes, while SGLT2 inhibitors can reduce insulin resistance and improve pancreatic beta-cell function.
Do SGLT2 inhibitors reduce the incidence of statin-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI?
Cohort (n=333)
No
Do SGLT2 inhibitors reduce the incidence of statin-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI?
SGLT2 inhibitors significantly reduce the risk of statin-induced abnormal blood glucose in non-diabetic patients with HFrEF following PCI without adversely affecting liver or kidney function.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors may attenuate statin-associated diabetes risk in post-PCI HFrEF; leaves open whether RCTs will confirm benefit.
BACKGROUND: Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. METHODS AND RESULTS: In total, 333 non-diabetes patients with heart failure with reduced ejection fraction (HFrEF) after percutaneous coronary intervention (PCI) are included. The enrolled patients are divided into a matched group (n = 198) and an SGLT2 inhibitors group (n = 135). There are no statistical differences in general information between the two groups before treatment. After a mean follow-up time of 13 months, abnormal blood glucose levels are significantly higher in the matched group than in the SGLT2 inhibitors group (6.06 vs. 0.74%, P < 0.05). There are no statistically significant differences in the alanine aminotransferase (ALT), uric acid (UA), and estimated glomerular filtration (eGFR) levels between the two groups. CONCLUSION: SGLT2 inhibitors play a significant protective role in reducing the risk of statins-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI, without increasing the burden on the heart, kidneys, and liver.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) after percutaneous coronary intervention (PCI) (n=333). SGLT2 inhibitors (dapagliflozin or empagliflozin) vs. Conventional treatments without SGLT2 inhibitors was evaluated on Abnormal blood glucose (RR 0.122, 95% CI 0.016, 0.929, p=<0.05). SGLT2 inhibitors reduced the incidence of statin-induced abnormal blood glucose compared to conventional treatment in non-diabetic patients with HFrEF after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: